Camkurt, Mehmet AkifGulpamuk, GizemFindikli, EbruElve, Rengin2020-03-262020-03-2620171738-10882093-4327https://dx.doi.org/10.9758/cpn.2017.15.2.181https://hdl.handle.net/20.500.12395/34982Venlafaxine is a serotonergic and noradrenergic reuptake inhibitor which is used for the treatment of depression. We report a case of galactorrhea in a patient with major depressive disorder after starting treatment with venlafaxine. In particular, we discuss the course of hyper and normoprolactinemic galactorrhea. We managed this side effect initially by dose reduction and further by switching to essitalopram. Physicians should be aware of endocrinologic side effects such as galactorrhea during the serotonin and noradrenaline reuptake inhibitor treatment.en10.9758/cpn.2017.15.2.181info:eu-repo/semantics/openAccessVenlafaxine hydrochlorideGalactorrheaProlactinDepressionTherapeuticsManagementEditorial15218118328449567Q2WOS:000401531000012Q3